By studying individual cardiac cells from heart failure patients, researchers have identified molecular signatures that point to biological mechanisms of disease.
Ó³»´«Ã½ researchers are contributing to Massachusetts’s COVID-19 diagnostic testing, developing new diagnostic technologies and data analysis tools, and generating new biological insights.
The Precision Cardiology Laboratory (PCL) of the Ó³»´«Ã½ and Bayer will focus on using innovative technologies to better understand cardiovascular disease and pursue new drug targets.